FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 304 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR How International Collaboration Has Helped Improve Cancer Care in Nepal April 8, 2021 FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... April 18, 2025 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... July 18, 2022 Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... March 11, 2026 Load more HOT NEWS Breast cancer surgery: ‘I’m proud of the tattoos inked across my... EMA Recommends Granting a Marketing Authorisation for Lurbinectedin High Frequency of Germline ATM Variants in CLL Tesco is making it even easier to support life-saving research
